NCT05103904
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant treatment 2 recruiting NCT04175912
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver treatment 2 active_not_recruiting NCT05269381
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors treatment 1 / 2 recruiting NCT05157451
Y-90 Versus SBRT for Inoperable HCC No drug interventions device_feasibility 2 withdrawn NCT04380545
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer treatment 1 / 2 suspended NCT05199285
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab treatment 2 recruiting NCT04430452
Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition treatment 2 recruiting NCT05168163
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer treatment 2 recruiting NCT04605731
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer treatment 1 recruiting NCT05092373
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax treatment 1 recruiting NCT01176604
Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma No drug interventions treatment Not Available completed NCT04022746
An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer No drug interventions diagnostic Not Available recruiting NCT03896646
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) No drug interventions treatment Not Available active_not_recruiting NCT03695250
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer treatment 1 / 2 terminated